Venetoclax: A new wave in hematooncology
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61988987%3A17110%2F18%3AA1901YXL" target="_blank" >RIV/61988987:17110/18:A1901YXL - isvavai.cz</a>
Alternative codes found
RIV/00843989:_____/18:E0107015
Result on the web
<a href="http://dx.doi.org/10.1016/j.exphem.2018.02.002" target="_blank" >http://dx.doi.org/10.1016/j.exphem.2018.02.002</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.exphem.2018.02.002" target="_blank" >10.1016/j.exphem.2018.02.002</a>
Alternative languages
Result language
angličtina
Original language name
Venetoclax: A new wave in hematooncology
Original language description
nhibitors of antiapoptotic proteins of the BCL2 family can successfully restart the deregulated process of apoptosis in malignant cells. Whereas nonselective agents have been limited by their affinity to different BCL2 members, thus inducing excessive toxicity, the highly selective BCL2 inhibitor venetoclax (ABT-199, Venclexta (TM)) has an acceptable safety profile. To date, it has been approved in monotherapy for the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL) with 17p deletion. Extension of indications can be expected in monotherapy and in combination regimens. Sensitivity to venetoclax is not common in lymphomas, but promising outcomes have been achieved in the mantle cell lymphoma group. Venetoclax is also active in multiple myeloma patients, especially in those with translocation t(11;14), even if high-risk features such as dell7p are also present. Surprisingly, positive results are being obtained in elderly acute myeloid leukemia patients, in whom inhibition of BCL2 is able to substantially increase the efficacy of low-dose cytarabine or hypomethylating agents. Here, we provide a summary of available results from clinical trials and describe a specific mechanism of action that stands behind the efficacy of venetoclax in hematological malignancies. (C) 2018 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology
Result continuities
Project
—
Continuities
O - Projekt operacniho programu
Others
Publication year
2018
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
EXPERIMENTAL HEMATOLOGY
ISSN
0301-472X
e-ISSN
1873-2399
Volume of the periodical
—
Issue of the periodical within the volume
61
Country of publishing house
US - UNITED STATES
Number of pages
16
Pages from-to
10-25
UT code for WoS article
000430637200002
EID of the result in the Scopus database
2-s2.0-85044294896